GE HealthCare and Mayo Clinic partner for new theranostics research study

The partnership will evaluate whether imaging- and biomarker-informed insights can support a more personalised approach to radioligand therapy (RLT). The partnership will evaluate whether imaging- and biomarker-informed insights can support a more personalised approach to radioligand therapy (RLT). Radioligand therapies ere pioneered by Novartis, with the Swiss pharma becoming the first company to gain US approval for a RLT with Lutathera (lutetium Lu 177 dotatate) in 2018. Credit: PixelBiss/Shutterstock.com GE HealthCare and Mayo Clinic are establishing a new research collaboration to advance personalised approaches to radioligand therapy (RLT) for advanced prostate cancer patients. RLT theranostics are a form of precision…

Source: Medical Device Network